Anterogen

Anterogen is a bio-venture company specializing in research and development of cell therapy products and orphan drugs using adult stem cells. Established a research institute in Boston in 2000, Anterogen began commercializing products using adipose-derived stem cells for the first time in Korea. In January 2012, we obtained a market authorization of Cupistem® injection as an adipose-derived stem cell therapy product for the first time in the world. Anterogen, an emerging global leader in the field of cell therapy products, has developed Adipocell® (for the treatment of depressed scar), Queencell® (for the regeneration of subcutaneous adipose tissue) and Cupistem® injection (for the treatment of Crohn's fistula) with accumulated experiences and R&D technology in stem cell therapy.